- Esperion continues to struggle to get NEXLETOL and NEXLIZET off the launch pad as COVID-19 headwinds disrupt their commercial efforts.
- The lackluster launch and relentless cash burn has crushed the share price to all-time lows.
- The cost cutting should help reduce the need for crushing dilution while we wait for the CLEAR Outcomes study top-line data readout that is expected in Q1 of 2023.
- The company reported preliminary unaudited Q3 results that shows NEXLETOL and NEXLIZET have made some progress.
- I have been waiting for a strong signal of a reversal or bottom before getting aggressive with my buying activity. The recent sell-off has forced me to pull out my “undervalued buy” playbook.
For further details see:
Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection